InvestSMART

Epsilon Healthcare Limited (ASX:EPN)

ALERT: Price-sensitive ASX Announcement for EPN
Current share price for EPN : $0.020 -0.001 (-4.76%)+
Announcement
Release
31 Aug 2026 5:44PM
Price at Release
$0.021
Full Release
download
Summary
Epsilon Healthcare Limited’s Appendix 4D and consolidated interim financial report for the half year ended 30 June 2026 reports a marked improvement in performance, with revenue from continuing operations rising 123% to $7.59 million and net loss after tax narrowing to $725,972 from $2.07 million in the prior corresponding period, driven by strong growth in its CDMO business, solid contributions from Epsilon Clinics and the newer Epsilon Pharmacy segment, and the absence of significant prior-year administration, legal and external accounting costs; EBITDA was positive at $254,869 and operating cash flow was positive at $1.03 million, while net tangible assets per security increased to 0.98 cents, net assets rose to $3.88 million, and cash increased to $1.29 million, although the group still had net current liabilities of about $1.05 million and remained reliant in part on director support and funding arrangements, including a new unsecured facility of up to $1.72 million maturing 31 December 2027; the report also notes completion of a small holding share sale facility that streamlined the share register, no dividends declared, no material post-balance-date events, and an independent auditor’s review conclusion that nothing had come to its attention to suggest the half-year financial report was not prepared in accordance with the Corporations Act 2001 and AASB 134.
Key Points
  • Half year ended 30 June 2026 with announcement dated 31 August 2026.
  • Revenue from continuing operations increased 123% to $7,585,957 from $3,401,788.
  • Net loss after tax attributable to members improved to $725,972 from $2,068,860.
  • EBITDA was positive at $254,869 for the half year.
  • Net cash inflow from operating activities was $1,029,149.
  • CDMO revenue increased 120% year on year and remained the largest revenue segment.
  • Pharmacy Services contributed $986,535 of revenue and Telehealth Medical Practice contributed $283,128.
  • No dividends were proposed or paid during the period.
  • Net tangible assets per security increased to 0.98 cents from 0.50 cents at 31 December 2025.
  • Cash and cash equivalents rose to $1,285,937 from $242,862 at 31 December 2025.
  • Net assets increased to $3,877,157 from $1,912,308 at 31 December 2025.
  • The group reported net current liabilities of $1,046,019 at 30 June 2026.
  • Management assessed the group as a going concern supported by positive operating cash flow, director support and funding facilities.
  • A new unsecured debt facility of up to $1.72 million was established with maturity on 31 December 2027 and had not been drawn at the report date.
  • The existing $2.0 million promissory note arrangement was terminated.
  • A small holding share sale facility generated about $489,753 for participating shareholders and reduced the share register from about 7,063 holders to about 1,688.
  • There were no significant events after balance date and no contingent liabilities reported.
  • The independent auditor issued an unmodified review conclusion on the half-year financial report.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.